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Methicillin-resistant Staphylococcus aureus (MRSA) and Autogenous
Saphenous Vein Grafts in Femoropopliteal Bypass Procedures
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Abstract: Do autogenous vein grafts provide resistance to graft infection in MRSA (Methicillin resistant Staphylococcus
aureus) patients undergoing vascular surgery? This paper presents two MRSA patients, who underwent femoral popliteal
bypass procedure with autogenous saphenous vein grafts. Despite prophylactic measures and all necessary care, both
patients had graft infections and died as a result of MRSA septicaemia. Our conclusion is that autogenous vein grafts do
not provide resistance to MRSA infection.
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In just 10 years, methicillin-resistant Staphylococcus
aureus (MRSA) has resulted in major health control
problems both in hospitals and in the community.
MRSA is a heterogeneous group of organisms, which
vary in virulence and epidemic potential. The impor-
tance of protection against this bacterium is of greater
concern because the most common mode of spread is
from the hands of nursing and medical personnel.1
As vein grafts are one of the most popular methods
by which vascular surgeons perform bypass, infection
of these bypass grafts presents a serious complication
to reconstructive vascular surgery. Some of the meth-
ods used by surgeons in an attempt to address this
are graft preservation, excision and repeat grafting
through clean tissue planes, as infection of prosthetic
arterial grafts remains a serious problem.
Traditionally, autogenous (saphenous) vein grafts
provided superior patency rates, with the consensus
of opinion being that vein grafts offered increased
resistance in patients with MRSA. Attempted graft
preservation has been the choice of treatment on
patients where infection is confined to a short segment
of an autogenous vein graft. It is widely believed thatPlease address all correspondence to: A. M. Khan, 89 Bank Street,
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any complications being rare. However, Wijesinghe
et al. recently reported cases of serious complications
with vein grafts in patients infected with MRSA.1 We
present two cases where autogenous vein grafts used
in MRSA patients had resulted in septicaemia and
death, the second case highlighting a rare event.
Both cases illustrate the need to reassess the use of
vein grafts in such cases.
Case 1
A 73-year male was admitted with acute onset of rest
pain and a cold left foot. On examination, femoral,
popliteal, and dorsalis pedis pulses were all absent.
An occluded left superficial femoral artery was
found on angiography. After failed angioplasty, a left
femoro-popliteal bypass was successfully performed.
A reversed left long saphenous vein graft was used for
the occluded site. The patient made an uneventful
postoperative recovery.
Two weeks later the patient was readmitted to
Accident & Emergency with a pyrexia, sweating and
rigors. His left leg was painful and on examination
there was spreading cellulitis with discharging pus
arising from the lower end of the groin incision.
Broad-spectrum antibiotics were started and the
wound debrided under local anaesthetic. MRSA wasC BY-NC-ND license.
Fig. 1
MRSA and Autogenous Saphenous Vein Grafts 59grown from the wound pus. Teicoplanin was started
intravenously.
Three days later, a swelling was noticed in his left
groin. Doppler ultrasound confirmed it to be a
pseudo-aneurysm. The groin was exposed and it was
discovered that the vein graft had given way at the
anastomosis. The perforated vein graft was subse-
quently removed and another femoropopliteal bypass
performed using the contralateral long saphenous vein.
Following surgery the patient continued with a
swinging pyrexia, rigors and erythema at the groin
site. He remained on intravenous antibiotics for 6
days, after which he died of septicaemia, renal failure
and ARDS.
Case 2
An 87-year-old male, with known MRSA infection,
was admitted with a worsening, painful left medial
malleolar ulcer. He subsequently underwent a below
knee popliteal bypass with a reversed long saphenous
vein graft for an occluded superficial femoral artery.
Vancomycin was administrated as prophylaxis.
Three weeks later he was re-admitted with a left
superficial groin haematoma. This was explored and
drained. The anastomotic site was found to be intact.
He was later discharged with no further events.
Five weeks later there was a second admission to
Accident & Emergency with hypovolmic shock and
cardiac arrest. Secondary haemorrhage had resulted
through a perforation in the middle part of the vein
graft (see Fig. 1). The patient was resuscitated and the
bleeding site controlled with pressure and elevation.
Doppler ultrasound confirmed the presence of a
pseudo-aneurysm.
During surgery, the graft and the adjacent artery
were found to have disintegrated at the upper end.
The haematoma was drained, the graft removed, the
artery ligated and an above knee amputation was
performed. The specimen vein graft grew pseudomo-
nas, and the wound itself grew MRSA. Intravenous
Teicoplanin was used along the course of these events.
Within the next 48 h, the distal end of the amputated
stump started to discharge foul pus. This was mana-
ged with daily wound dressing, debridement and
antibiotics. Some four weeks later the patient died of
septicaemia.
Discussion
Methicillin-resistant Staphylococcus aureus (MRSA) is a
highly virulent pathogen. It has become a majornosocomial pathogen, accounting for its endemic
nature in community hospitals, long term care facil-
ities and tertiary care hospitals.2
With the frail and debilitated vascular group of
MRSA patients, this is a major cause of morbidity
and mortality.3 It has led to MRSA sepsis in 9% of all
major vascular surgical cases and is a cause of death in
2% of patients.4 Graft infection is a catastrophic com-
plication of surgery with mortality rates from 13±33%,
and amputation rates of 19±53%.4 The incidence has
probably been reduced by antibiotic prophylaxis, but
the overall prevalence is increasing in parallel with the
expansion in reconstructive vascular surgery and the
emergence of MRSA.
Traditionally, the consensus of opinion favoured the
use of vein grafts in MRSA patients, as it is thought thatEJVES Extra, 2002
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ever, Ruddle et al. found that stripped venous grafts are
frequently contaminated.5 The groin is a major source
of contamination with approximately 50% of graft
infections occurring here. MRSA is the most commonly
found organism.6 In both our cases, reversed saphe-
nous vein grafts were used as the bypass conduit.
However it led to a course of drastic events; 3±4
weeks after surgery both patients developed groin
wound haematoma, anastomotic leaks and eventually
died. The second patient presented with graft perfor-
ation separate from the anastomoses which is a rare
event and which was presumably caused by MRSA
infection at one of the ligated tributary sites.
Evidence from vascular centres suggest that MRSA
is a growing problem with an increasing number
of centres reporting patients in whom MRSA was
associated with vein graft failure, particularly second-
ary haemorrhage. Chalmers et al. showed that of the
15 patients with infrainguinal MRSA prosthetic graft
infections, 10 required amputations with a further
four dying from MRSA sepsis.7
The question arises as to how can we prevent and
control this problem. There seems to be no one
answer but the following are important points for
consideration.
An attempt to eradicate MRSA infection prior to
surgery should be considered. In those patients in
whom elective surgery is undertaken. There should
be reconsideration of the risk/benefit ratios of recon-
structive surgery in lower limb occlusive disease and
angioplasty should be considered, as an alternative.
Other graft options are now becoming increasingly
available. Rifampicin soaked dacron, is an option as
an alternative conduit. Vicaretti et al. showed that
rifampicin reduced the rate of abscess formation, ana-
stomotic disruption and graft thrombosis, when the
inoculating organism was MRSA.9 Another conduit
is arterial allograft, a material that has proven resist-
ance to staphylococcal infection, but it has limited
availability in the U.K.
It can be reasoned that once the surgeon becomes
aware of the presence of MRSA, the primary treatment
should be graft excision plus amputation ± the aim
being to preserve life rather than limb.8 The routine
use of vancomycin as prophylaxis remains controver-
sial and therefore selective use should be undertakenEJVES Extra, 2002with advice from microbiologists. The blanket treat-
ment of all vascular patients with MRSA prophylaxis
also needs to be reviewed as this could lead to the
development of more resistant strains.
When colonisation/infection occurs in MRSA
patients, we need more reliable data to ascertain the
true incidence of the problem. Evidence suggests that
strict isolation units, coupled with scrupulous hand
washing and a multidisciplinary approach involving
the nursing staff, medical staff and infection control
team, may reduce MRSA transmission.
Conclusions
Our conclusion is that to avoid the above catastrophic
consequences, we advocate that the autogenous
venous graft should not be used for bypass surgery
in MRSA patients, as they are not resistant to MRSA
infection.
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